Monitoring HPV DNA in patients with throat cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the presence of circulating tumor HPV DNA in the blood of patients diagnosed with HPV-positive oropharyngeal squamous cell carcinoma. Participants will provide blood samples before treatment, weekly during treatment, and at all follow-up appointments to assess the potential of HPV DNA as a marker for treatment response and early detection of relapse. The study seeks to determine if the presence of HPV DNA one month post-treatment can help identify remaining tumors or recurrences within two years. By integrating HPV DNA analysis with traditional imaging techniques, the study hopes to improve patient outcomes through earlier detection of cancer recurrence.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Only patients with an HPV-positive primary tumour will eventually be eligible for inclusion.

   Non-detectable ctHPVDNA at diagnosis will not be a reason for exclusion.
2. Age \>18 years.
3. Able to give informed consent.
4. The patient will be treated with curative intent.

Exclusion Criteria:

Patients with a short life expectancy, psychiatric or addictive disorders, or other medical conditions which might impair patient compliance may be excluded at the discretion of the investigator.

Where it's running

• Dept. of ORL-HNS
  Lund, Skåne County, Sweden Recruiting

Study contacts

• Principal investigator: Johanna Sjövall, MD,PhD — Dept. of clincial sciences, Lund University
• Study coordinator: Johanna Sjövall, MD, PhD
• Email: johanna.sjovall@med.lu.se
• Phone: +4646172164

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sacituzumab govitecan plus cetuximab for recurrent or metastatic head and neck squamous cell cancer

  This trial will test whether combining sacituzumab govitecan with cetuximab works and is safe for people whose head and neck squamous cell cancer has returned or spread after prior immunotherapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07063212

• New blood test to reduce radiation in HPV-related throat cancer treatment

  This study is testing a new blood test to see if it can help identify patients with HPV-related throat cancer who might not need radiation after surgery, aiming to reduce side effects while keeping survival rates high.

  Recruiting at 2 sites Phase 2 University of Maryland, Baltimore · Baltimore, Maryland and 4 other locations · NCT06088381

• New method to monitor HPV16-related throat cancer recurrence

  This study is testing if measuring HPV16 DNA in the blood can help doctors better monitor throat cancer patients for signs of recurrence, so they can provide more personalized follow-up care.

  Recruiting at 10 sites Phase 2 Unicancer · Saint-Denis, La Réunion and 15 other locations · NCT05582122

• Detecting oral and throat cancers using a saliva test

  This study is testing a saliva test to see if it can help detect oral and throat cancers early in people, including those who are healthy and those with existing conditions.

  Recruiting Viome · New York, New York · NCT05451303

• Observing HPV DNA and genetic markers in oropharyngeal cancer

  This study is testing if checking for certain gene changes and HPV DNA in the blood can help predict if oropharyngeal cancer will come back in newly diagnosed patients.

  Recruiting at 2 sites UNC Lineberger Comprehensive Cancer Center · Rochester, Minnesota and 2 other locations · NCT04564989

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.